# Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma

> **NCT06304636** · PHASE1 · TERMINATED · sponsor: **Cartesian Therapeutics** · enrollment: 4 (actual)

## Conditions studied

- Refractory Multiple Myeloma
- Relapsed Multiple Myeloma

## Interventions

- **DRUG:** Descartes-15

## Key facts

- **NCT ID:** NCT06304636
- **Lead sponsor:** Cartesian Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-06-19
- **Primary completion:** 2025-04-14
- **Final completion:** 2025-11-13
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Phase 1 enrollment completed. Further clinical development terminated
- **Last updated:** 2025-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06304636

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06304636, "Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06304636. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*